Direct-to-consumer testing (DTCT) refers to commercial laboratory tests initiated by laypersons without the involvement of healthcare professionals. As this market grows in size and variety of products, a clear definition of DTCT to ground the conceptualization of their harms and benefits is needed. We describe how three different modalities of DTCT (home self-testing, self-sampled tests, and direct access tests) present caveats to the traditional testing process ('brain-to-brain loop'), and how this might differ between medical vs. non-medical laboratories. We make recommendations for ways to improve quality and reduce errors with respect to DTCT. The potential benefits and harms of DTCT will invariably depend on the context and situation of individual consumers and the types of tests involved. Importantly, implications for both consumers and the healthcare system should be considered, such as the effects on improving health outcomes and reducing unnecessary testing and use of clinical resources. 'Consumer initiation' must be a central defining characteristic of DTCT, to clearly demarcate the key drawbacks as well as opportunities of this type of testing from a laboratory specialists' perspective. The concept of 'consumer initiated testing' should also help define DTCT regulation, and provide a locus of efforts to support consumers as the main decision-makers in the purchasing and conducting of these tests in the absence of clinician gatekeeping.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1515/cclm-2024-0876 | DOI Listing |
J Prev Interv Community
December 2024
Utah Volunteer Income Tax Assistance (VITA) Program, Salt Lake City, Utah, USA.
The Earned Income Tax Credit (EITC) is an important economic safety net for many working families across America. Enacted in 1975, the credit provides credit to low- and moderate-income households with labor income. Receipt of the EITC has been demonstrated to provide substantial benefits to direct recipients, benefits that cascade intergenerationally, and benefits for communities in which recipients reside.
View Article and Find Full Text PDFCureus
November 2024
Department of Ophthalmology, Morsani College of Medicine, University of South Florida, Tampa, USA.
Objectives To determine if direct-to-consumer (DTC) laboratory testing is less expensive for patients, as is generally advertised, and whether it has any role in managing uninsured or underinsured patients. Methods The costs of six commonly ordered laboratory tests were obtained through two major DTC laboratories and compared with 42 physician-ordered, hospital-based laboratories in Florida. The costs of DTC tests were also compared to concurrent reimbursements from Medicare and Medicaid.
View Article and Find Full Text PDFObjective: Direct-to-consumer (D2C) genetic tests are increasingly accessible to pet owners, with commercial genetic companies entering veterinary distribution markets. This study evaluated veterinary care providers' (VCPs) awareness of the D2C genetic industry, experiences with clients' inquiries, perceptions of clinical utility, and confidence in interpreting test results.
Methods: Veterinary care providers attending a professional conference (February 19 through 23, 2023) were invited to complete an online survey.
Microbiome
December 2024
Pharmabiotic Research Institute, 11100, Narbonne, France.
Background: In recent years, human microbiome research has flourished and has drawn attention from both healthcare professionals and general consumers as the human microbiome is now recognized as having a significant influence on human health. This has led to the emergence of companies offering microbiome testing services. Some of these services are sold directly to the consumer via companies' websites or via medical laboratory websites.
View Article and Find Full Text PDFCell Genom
December 2024
African Computational Genomics (TACG) Research Group, The MRC Uganda Medical Informatics Centre (UMIC), MRC/UVRI and LSHTM, Entebbe, Uganda; Precision Health University Research Institute, Queen Mary University of London, London, UK.
Achieving diverse representation in biomedical data is critical for healthcare equity. Failure to do so perpetuates health disparities and exacerbates biases that may harm patients with underrepresented ancestral backgrounds. We present a quantitative assessment of representation in datasets used across human genomics, including genome-wide association studies (GWASs), pharmacogenomics, clinical trials, and direct-to-consumer (DTC) genetic testing.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!